You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameChlordiazepoxide
Accession NumberDB00475  (APRD00682)
TypeSmall Molecule
GroupsApproved, Illicit
Description

An anxiolytic benzodiazepine derivative with anticonvulsant, sedative, and amnesic properties. It has also been used in the symptomatic treatment of alcohol withdrawal. [PubChem]

Structure
Thumb
Synonyms
SynonymLanguageCode
7-chloro-2-Methylamino-5-phenyl-3H-1,4-benzodiazepin-4-oxideNot AvailableNot Available
CDPNot AvailableNot Available
ChloradiazepoxideNot AvailableNot Available
Chlordiazepoxide baseNot AvailableNot Available
ChlordiazepoxidumLatinINN
ClopoxideNot AvailableNot Available
HelogaphenNot AvailableNot Available
LibritabsNot AvailableNot Available
MethaminodiazepoxideNot AvailableNot Available
MultumNot AvailableNot Available
RisolidNot AvailableNot Available
SilibrinNot AvailableNot Available
TropiumNot AvailableNot Available
Prescription ProductsNot Available
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Chlordiazepoxide Hydrochloridecapsule10 mgoralBarr Laboratories Inc.1990-09-30Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Chlordiazepoxide Hydrochloridecapsule5 mgoralBarr Laboratories Inc.1976-07-01Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Chlordiazepoxide Hydrochloridecapsule25 mgoralBarr Laboratories Inc.1976-07-02Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Chlordiazepoxide Hydrochloridecapsule, gelatin coated5 mgoralAv Kare, Inc.2002-09-26Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Chlordiazepoxide Hydrochloridecapsule, gelatin coated10 mgoralAv Kare, Inc.2002-09-26Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Chlordiazepoxide Hydrochloridecapsule, gelatin coated25 mgoralAv Kare, Inc.2002-09-26Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Chlordiazepoxide Hydrochloridecapsule25 mgoralPd Rx Pharmaceuticals, Inc.2010-12-06Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Chlordiazepoxide Hydrochloridecapsule, gelatin coated5 mgoralSolco Healthcare US LLC2010-05-15Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Chlordiazepoxide Hydrochloridecapsule, gelatin coated10 mgoralSolco Healthcare US LLC2010-05-15Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Chlordiazepoxide Hydrochloridecapsule, gelatin coated25 mgoralSolco Healthcare US LLC2010-05-15Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Chlordiazepoxide Hydrochloridecapsule25 mgoralREMEDYREPACK INC.2011-08-01Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Chlordiazepoxide Hydrochloridecapsule10 mgoralREMEDYREPACK INC.2011-08-04Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Chlordiazepoxide Hydrochloridecapsule5 mgoralREMEDYREPACK INC.2011-08-11Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Chlordiazepoxide Hydrochloridecapsule25 mgoralREMEDYREPACK INC.2011-05-10Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Chlordiazepoxide Hydrochloridecapsule25 mgoralREMEDYREPACK INC.2011-10-31Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Chlordiazepoxide Hydrochloridecapsule25 mgoralREMEDYREPACK INC.2012-03-14Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Chlordiazepoxide Hydrochloridecapsule25 mgoralA S Medication Solutions Llc1976-07-02Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Chlordiazepoxide Hydrochloridecapsule25 mgoralMylan Institutional Inc.1994-05-06Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Chlordiazepoxide Hydrochloridecapsule5 mgoralMylan Institutional Inc.1995-12-08Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Chlordiazepoxide Hydrochloridecapsule10 mgoralMylan Institutional Inc.1996-03-05Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Chlordiazepoxide Hydrochloridecapsule25 mgoralA S Medication Solutions Llc1976-07-02Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Chlordiazepoxide Hydrochloridecapsule10 mgoralPhysicians Total Care, Inc.1994-12-09Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Chlordiazepoxide Hydrochloridecapsule25 mgoralPhysicians Total Care, Inc.1993-03-24Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Chlordiazepoxide Hydrochloridecapsule5 mgoralPhysicians Total Care, Inc.1993-01-01Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Chlordiazepoxide Hydrochloridecapsule5 mgoralCardinal Health2011-04-01Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Chlordiazepoxide Hydrochloridecapsule10 mgoralCardinal Health2011-04-01Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Chlordiazepoxide Hydrochloridecapsule25 mgoralCardinal Health2011-04-01Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Chlordiazepoxide Hydrochloridecapsule, gelatin coated5 mgoralGolden State Medical Supply, Inc.2010-05-15Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Chlordiazepoxide Hydrochloridecapsule, gelatin coated10 mgoralGolden State Medical Supply, Inc.2010-05-15Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Chlordiazepoxide Hydrochloridecapsule, gelatin coated25 mgoralGolden State Medical Supply, Inc.2010-05-15Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Chlordiazepoxide Hydrochloridecapsule25 mgoralbryant ranch prepack2010-12-06Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Chlordiazepoxide Hydrochloridecapsule10 mgoralbryant ranch prepack1990-09-30Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Chlordiazepoxide Hydrochloridecapsule25 mgoralTYA Pharmaceuticals1976-07-02Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Chlordiazepoxide Hydrochloridecapsule25 mgoralContract Pharmacy Services Pa2010-04-07Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Over the Counter ProductsNot Available
International Brands
NameCompany
AngirexNot Available
EleniumPolfa Tarchomin
KlopoxidNycomed
LibriumAbbott
NapotonNot Available
RadepurAWD
RisolidActavis
SilibrinNot Available
SonimenNot Available
Brand mixtures
Brand NameIngredients
Apo-Chlorax CapChlordiazepoxide Hydrochloride + Clidinium Bromide
Corium CapChlordiazepoxide Hydrochloride + Clidinium Bromide
LibotrypChlordiazepoxide Hydrochloride + Amitriptyline
LibraxChlordiazepoxide Hydrochloride + Clidinium Bromide
Pro ChloraxChlordiazepoxide Hydrochloride + Clidinium Bromide
Salts
Name/CASStructureProperties
Chlordiazepoxide Hydrochloride
438-41-5
Thumb
  • InChI Key: PRNVHVUEIITLRV-UHFFFAOYSA-N
  • Monoisotopic Mass: 335.059217531
  • Average Mass: 336.216
DBSALT000632
Categories
CAS number58-25-3
WeightAverage: 299.755
Monoisotopic: 299.082539792
Chemical FormulaC16H14ClN3O
InChI KeyANTSCNMPPGJYLG-UHFFFAOYSA-N
InChI
InChI=1S/C16H14ClN3O/c1-18-15-10-20(21)16(11-5-3-2-4-6-11)13-9-12(17)7-8-14(13)19-15/h2-9H,10H2,1H3,(H,18,19)
IUPAC Name
7-chloro-2-(methylamino)-5-phenyl-3H-1,4λ⁵-benzodiazepin-4-one
SMILES
CNC1=NC2=C(C=C(Cl)C=C2)C(C2=CC=CC=C2)=N(=O)C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as 1,4-benzodiazepines. These are organic compounds containing a benzene ring fused to a 1,4-azepine.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassBenzodiazepines
Sub Class1,4-benzodiazepines
Direct Parent1,4-benzodiazepines
Alternative Parents
Substituents
  • 1,4-benzodiazepine
  • Imidolactam
  • Benzenoid
  • Monocyclic benzene moiety
  • Aryl halide
  • Aryl chloride
  • Nitrone
  • Azacycle
  • Organic 1,3-dipolar compound
  • Propargyl-type 1,3-dipolar organic compound
  • Allyl-type 1,3-dipolar organic compound
  • Carboxylic acid amidine
  • Amidine
  • Hydrocarbon derivative
  • Organic salt
  • Organonitrogen compound
  • Organochloride
  • Organohalogen compound
  • Organic cation
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationFor the management of anxiety disorders or for the short-term relief of symptoms of anxiety, withdrawal symptoms of acute alcoholism, and preoperative apprehension and anxiety.
PharmacodynamicsChlordiazepoxide has antianxiety, sedative, appetite-stimulating and weak analgesic actions. The drug seems to block EEG arousal from stimulation in the brain stem reticular formation. The drug has been studied extensively in many species of animals and these studies are suggestive of action on the limbic system of the brain, which recent evidence indicates is involved in emotional responses. Hostile monkeys were made tame by oral drug doses which did not cause sedation. Chlordiazepoxide revealed a "taming" action with the elimination of fear and aggression. The taming effect of chlordiazepoxide was further demonstrated in rats made vicious by lesions in the septal area of the brain. The drug dosage which effectively blocked the vicious reaction was well below the dose which caused sedation in these animals.
Mechanism of actionChlordiazepoxide binds to stereospecific benzodiazepine (BZD) binding sites on GABA (A) receptor complexes at several sites within the central nervous system, including the limbic system and reticular formation. This results in an increased binding of the inhibitory neurotransmitter GABA to the GABA(A) receptor.BZDs, therefore, enhance GABA-mediated chloride influx through GABA receptor channels, causing membrane hyperpolarization. The net neuro-inhibitory effects result in the observed sedative, hypnotic, anxiolytic, and muscle relaxant properties.
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

Hepatic.

Route of eliminationChlordiazepoxide is excreted in the urine, with 1% to 2% unchanged and 3% to 6% as conjugate.
Half life24-48 hours
ClearanceNot Available
ToxicityLD50=537 mg/kg (Orally in rats). Signs of overdose include respiratory depression, muscle weakness, somnolence (general depressed activity).
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9758
Caco-2 permeable+0.5868
P-glycoprotein substrateSubstrate0.6705
P-glycoprotein inhibitor INon-inhibitor0.521
P-glycoprotein inhibitor IINon-inhibitor0.7434
Renal organic cation transporterNon-inhibitor0.5502
CYP450 2C9 substrateNon-substrate0.6991
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateSubstrate0.7408
CYP450 1A2 substrateInhibitor0.7564
CYP450 2C9 substrateNon-inhibitor0.6038
CYP450 2D6 substrateNon-inhibitor0.7862
CYP450 2C19 substrateNon-inhibitor0.5
CYP450 3A4 substrateInhibitor0.7067
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.6372
Ames testNon AMES toxic0.593
CarcinogenicityNon-carcinogens0.7108
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.8520 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9198
hERG inhibition (predictor II)Non-inhibitor0.8828
Pharmacoeconomics
Manufacturers
  • Valeant pharmaceuticals international
  • Abbott laboratories pharmaceutical products div
  • Rachelle laboratories inc
  • Ascot hosp pharmaceuticals inc div travenol laboratories inc
  • Barr laboratories inc
  • John j ferrante
  • Halsey drug co inc
  • Impax laboratories inc
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Lederle laboratories div american cyanamid co
  • Mm mast and co
  • Mylan pharmaceuticals inc
  • Parke davis div warner lambert co
  • Pioneer pharmaceuticals inc
  • Purepac pharmaceutical co
  • Roxane laboratories inc
  • Sandoz inc
  • Superpharm corp
  • Teva pharmaceuticals usa inc
  • Usl pharma inc
  • Vangard laboratories inc div midway medical co
  • Watson laboratories inc
  • West ward pharmaceutical corp
  • Alra laboratories inc
Packagers
Dosage forms
FormRouteStrength
Capsuleoral10 mg
Capsuleoral25 mg
Capsuleoral5 mg
Capsule, gelatin coatedoral10 mg
Capsule, gelatin coatedoral25 mg
Capsule, gelatin coatedoral5 mg
Prices
Unit descriptionCostUnit
Librax 2.5-5 mg capsule6.5USD capsule
Librax capsule5.78USD capsule
Librium 25 mg capsule2.14USD capsule
Limbitrol DS 10-25 mg tablet1.93USD tablet
Librium 10 mg capsule1.61USD capsule
Librium 5 mg capsule0.84USD capsule
Chlordiazepoxide 25 mg capsule0.72USD capsule
ChlordiazePOXIDE HCl 25 mg capsule0.32USD capsule
ChlordiazePOXIDE HCl 10 mg capsule0.31USD capsule
ChlordiazePOXIDE HCl 5 mg capsule0.31USD capsule
Chlordiazepoxide 5 mg capsule0.2USD capsule
Apo-Chlordiazepoxide 25 mg Capsule0.17USD capsule
Chlordiazepoxide 10 mg capsule0.14USD capsule
Apo-Chlordiazepoxide 10 mg Capsule0.11USD capsule
Apo-Chlordiazepoxide 5 mg Capsule0.07USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point236-236.5Sternbach, L.H.; US. Patent 2,893,992; July 7,1959; assigned to Hoffmann-LaRoche, Inc.
water solubility2000 mg/LYALKOWSKY,SH & DANNENFELSER,RM (1992)
logP2.44HANSCH,C ET AL. (1995)
pKa4.8MERCK INDEX (1996)
Predicted Properties
PropertyValueSource
Water Solubility0.0199 mg/mLALOGPS
logP2.01ALOGPS
logP3.05ChemAxon
logS-4.2ALOGPS
pKa (Strongest Acidic)18.52ChemAxon
pKa (Strongest Basic)6.43ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area53.14 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity87.34 m3·mol-1ChemAxon
Polarizability30.97 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis Reference

Sternbach, L.H.; US. Patent 2,893,992; July 7,1959; assigned to Hoffmann-LaRoche, Inc.

General Reference
  1. Skerritt JH, Johnston GA: Enhancement of GABA binding by benzodiazepines and related anxiolytics. Eur J Pharmacol. 1983 May 6;89(3-4):193-8. Pubmed
  2. Oishi R, Nishibori M, Itoh Y, Saeki K: Diazepam-induced decrease in histamine turnover in mouse brain. Eur J Pharmacol. 1986 May 27;124(3):337-42. Pubmed
  3. Earley JV, Fryer RI, Ning RY: Quinazolines and 1,4-benzodiazepines. LXXXIX: Haptens useful in benzodiazepine immunoassay development. J Pharm Sci. 1979 Jul;68(7):845-50. Pubmed
  4. Olive G, Dreux C: [Pharmacologic bases of use of benzodiazepines in pereinatal medicine] Arch Fr Pediatr. 1977 Jan;34(1):74-89. Pubmed
  5. Vozeh S: [Pharmacokinetic of benzodiazepines in old age] Schweiz Med Wochenschr. 1981 Nov 21;111(47):1789-93. Pubmed
External Links
ATC CodesN05BA02
AHFS Codes
  • 28:24.08
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (74.9 KB)
Interactions
Drug Interactions
Drug
AminophyllineTheophylline Derivatives may diminish the therapeutic effect of Benzodiazepines.
AprepitantMay increase the serum concentration of CYP3A4 Substrates.
BosentanMay decrease the serum concentration of CYP3A4 Substrates.
BuprenorphineCNS Depressants may enhance the CNS depressant effect of Buprenorphine.
ClozapineMay enhance the adverse/toxic effect of CloZAPine.
ConivaptanMay increase the serum concentration of CYP3A4 Substrates.
DabrafenibMay decrease the serum concentration of CYP3A4 Substrates.
DasatinibMay increase the serum concentration of CYP3A4 Substrates.
DeferasiroxMay decrease the serum concentration of CYP3A4 Substrates.
DisulfiramMay increase the serum concentration of ChlordiazePOXIDE.
DoxylamineMay enhance the CNS depressant effect of CNS Depressants.
DronabinolMay enhance the CNS depressant effect of CNS Depressants.
DroperidolMay enhance the CNS depressant effect of CNS Depressants.
FosaprepitantMay increase the serum concentration of CYP3A4 Substrates.
FosphenytoinMay increase the serum concentration of Fosphenytoin. Short-term exposure to benzodiazepines may not present as much risk as chronic therapy. Exceptions: ALPRAZolam.
Gamma Hydroxybutyric AcidMay enhance the CNS depressant effect of Sodium Oxybate.
HydrocodoneCNS Depressants may enhance the CNS depressant effect of Hydrocodone.
HydroxyzineMay enhance the CNS depressant effect of CNS Depressants.
IvacaftorMay increase the serum concentration of CYP3A4 Substrates.
LULICONAZOLEMay increase the serum concentration of CYP3A4 Substrates.
Magnesium SulfateMay enhance the CNS depressant effect of CNS Depressants.
MethadoneMay enhance the CNS depressant effect of Methadone.
MethotrimeprazineCNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.
MetyrosineCNS Depressants may enhance the sedative effect of Metyrosine.
MifepristoneMay increase the serum concentration of CYP3A4 Substrates.
MirtazapineCNS Depressants may enhance the CNS depressant effect of Mirtazapine.
MitotaneMay decrease the serum concentration of CYP3A4 Substrates.
NabiloneMay enhance the CNS depressant effect of CNS Depressants.
OlanzapineOLANZapine may enhance the adverse/toxic effect of Benzodiazepines.
OrphenadrineCNS Depressants may enhance the CNS depressant effect of Orphenadrine.
PerampanelMay enhance the CNS depressant effect of CNS Depressants.
PhenytoinMay increase the serum concentration of Phenytoin. Short-term exposure to benzodiazepines may not present as much risk as chronic therapy. Exceptions: ALPRAZolam.
PramipexoleCNS Depressants may enhance the sedative effect of Pramipexole.
RopiniroleCNS Depressants may enhance the sedative effect of ROPINIRole.
RotigotineCNS Depressants may enhance the sedative effect of Rotigotine.
RufinamideMay enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced.
SiltuximabMay decrease the serum concentration of CYP3A4 Substrates.
SimeprevirMay increase the serum concentration of CYP3A4 Substrates.
SuvorexantCNS Depressants may enhance the CNS depressant effect of Suvorexant.
TapentadolMay enhance the CNS depressant effect of CNS Depressants.
TeduglutideMay increase the serum concentration of Benzodiazepines.
ThalidomideCNS Depressants may enhance the CNS depressant effect of Thalidomide.
TheophyllineTheophylline Derivatives may diminish the therapeutic effect of Benzodiazepines.
TocilizumabMay decrease the serum concentration of CYP3A4 Substrates.
YohimbineMay diminish the therapeutic effect of Antianxiety Agents.
ZolpidemCNS Depressants may enhance the CNS depressant effect of Zolpidem.
Food Interactions
  • Avoid alcohol.
  • Take without regard to meals.

Targets

1. GABA-A receptor (anion channel)

Kind: protein group

Organism: Human

Pharmacological action: yes

Actions: positive allosteric modulator

Components

Name UniProt ID Details
Gamma-aminobutyric acid receptor subunit alpha-1 P14867 Details
Gamma-aminobutyric acid receptor subunit alpha-2 P47869 Details
Gamma-aminobutyric acid receptor subunit alpha-3 P34903 Details
Gamma-aminobutyric acid receptor subunit alpha-4 P48169 Details
Gamma-aminobutyric acid receptor subunit alpha-5 P31644 Details
Gamma-aminobutyric acid receptor subunit alpha-6 Q16445 Details
Gamma-aminobutyric acid receptor subunit beta-1 P18505 Details
Gamma-aminobutyric acid receptor subunit beta-2 P47870 Details
Gamma-aminobutyric acid receptor subunit beta-3 P28472 Details
Gamma-aminobutyric acid receptor subunit delta O14764 Details
Gamma-aminobutyric acid receptor subunit epsilon P78334 Details
Gamma-aminobutyric acid receptor subunit gamma-1 Q8N1C3 Details
Gamma-aminobutyric acid receptor subunit gamma-2 P18507 Details
Gamma-aminobutyric acid receptor subunit gamma-3 Q99928 Details
Gamma-aminobutyric acid receptor subunit pi O00591 Details
Gamma-aminobutyric acid receptor subunit theta Q9UN88 Details

References:

  1. Skerritt JH, Johnston GA: Enhancement of GABA binding by benzodiazepines and related anxiolytics. Eur J Pharmacol. 1983 May 6;89(3-4):193-8. Pubmed

Enzymes

1. Cytochrome P450 3A4

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Cytochrome P450 3A4 P08684 Details

References:

  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

2. Cytochrome P450 2D6

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Cytochrome P450 2D6 P10635 Details

References:

  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on April 03, 2014 16:54